By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 6/20/2017 7:18:03 AM
Ipsen (IPN.PA) Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults 6/16/2017 10:57:30 AM
Ipsen (IPN.PA): Disclosure Of Transactions In Own Shares Between 05/06/2017 And 09/06/2017 6/15/2017 6:54:30 AM
Ipsen (IPN.PA) Initiates Share Buy-Back Program To Cover Its Free Performance Share Allocation Plan 6/8/2017 7:22:42 AM
Combined Shareholders’ Meeting Of Ipsen (IPN.PA) Held On 7 June 2017 6/7/2017 11:59:31 AM
Ipsen (IPN.PA) Presents Its New Strategy And Improved 2020 Financial Targets 5/11/2017 7:07:58 AM
Ipsen (IPN.PA) Completes Acquisition Of Select Consumer Healthcare Products From Sanofi (SNY) 5/8/2017 6:31:59 AM
Ipsen (IPN.PA) Reports Strong First Quarter 2017 Sales Growth Of 19,1% 4/27/2017 5:58:23 AM
Resolutions Submitted To Ipsen (IPN.PA)’s Shareholders' Meeting On June 7, 2017 4/25/2017 11:47:05 AM
Ipsen (IPN.PA) Announces Five Poster Presentations Of Dysport (Abobotulinumtoxina) Data At The 2017 Annual Meeting Of American Academy of Neurology 4/19/2017 8:46:06 AM